Extending therapy options in treating lipid disorders - A clinical review of cerivastatin, a novel HMG-CoA reductase inhibitor

被引:29
作者
Stein, EA [1 ]
机构
[1] Med Res Labs, Highland Hts, KY 41076 USA
关键词
D O I
10.2165/00003495-199856001-00004
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Cerivastatin is a third generation pure enantiomeric HMG-CoA reductase inhibitor. It reduces low density lipoprotein (LDL)-cholesterol by 22 to 44% at doses of 0.1 to 0.8 mg/day. The drug has been extensively evaluated for more than 5 years in clinical trials and is currently marketed in a number of countries at doses of 0.1 to 0.3 mg/day. Cerivastatin has been tested in more than 4000 patients during extensive phase II and III studies. About 40% of patients in these trials were women, and many participants were aged between 65 and 75 years. The trial populations had moderate to severe hypercholesterolaemia, with mean baseline LDL-cholesterol levels of approximately 5.2 mmol/L (200 mg/dl). In large phase III trials, cerivastatin, over the dosage range of 0.1 to 0.4 mg/day, reduced LDL-cholesterol by 22.4 to 36.1% from baseline. As with other HMG-CoA reductase inhibitors, the log-linear dose-response curve of cerivastatin showed a 6% additional decrease in mean LDL-cholesterol levels for each doubling of the daily dose, with no plateau effect noted at the highest dosage yet tested (0.8 mg/day). High density lipoprotein cholesterol levels increased by 4 to 10% during cerivastatin therapy. This effect, which was consistent with that of other HMG-CoA reductase inhibitors, was not dose related. As has been found with other statins, the triglyceride-lowering effects of cerivastatin are dependent on baseline triglyceride levels, with very small reductions occurring in patients with low initial levels [<1.7 mmol/L(150 mg/dl)], and larger dose-dependent reductions of up to 36% with the 0.4 mg/day dose observed in patients with baseline triglyceride levels >2.8 mmol/L (250 mg/dl). Cerivastatin was well tolerated in all studies. Cerivastatin recipients and recipients of other HMG-CoA reductase inhibitors experienced a similar incidence of adverse events (including hepatic transaminase elevations) in comparative studies. Cerivastatin is an effective and safe lipid-lowering agent for most patients with hypercholesterolaemia.
引用
收藏
页码:25 / 31
页数:7
相关论文
共 25 条
  • [1] Cerivastatin - Multicentre, double-blind comparison with placebo and simvastatin in primary hypercholesterolaemia
    Betteridge, DJ
    [J]. ATHEROSCLEROSIS, 1997, 134 (1-2) : 45 - 46
  • [2] BETTERIDGE DJ, 1997, CERIVASTATIN, P29
  • [3] Cerivastatin: pharmacology of a novel synthetic and highly active HMG-CoA reductase inhibitor
    Bischoff, H
    Angerbauer, R
    Bender, J
    Bischoff, E
    Faggiotto, A
    Petzinna, D
    Pfitzner, J
    Porter, MC
    Schmidt, D
    Thomas, G
    [J]. ATHEROSCLEROSIS, 1997, 135 (01) : 119 - 130
  • [4] Bischoff H, 1997, ATHEROSCLEROSIS, V130, P93
  • [5] EXPANDED CLINICAL-EVALUATION OF LOVASTATIN (EXCEL) STUDY RESULTS .1. EFFICACY IN MODIFYING PLASMA-LIPOPROTEINS AND ADVERSE EVENT PROFILE IN 8245 PATIENTS WITH MODERATE HYPERCHOLESTEROLEMIA
    BRADFORD, RH
    SHEAR, CL
    CHREMOS, AN
    DUJOVNE, C
    DOWNTON, M
    FRANKLIN, FA
    GOULD, AL
    HESNEY, M
    HIGGINS, J
    HURLEY, DP
    LANGENDORFER, A
    NASH, DT
    POOL, JL
    SCHNAPER, H
    [J]. ARCHIVES OF INTERNAL MEDICINE, 1991, 151 (01) : 43 - 49
  • [6] The efficacy and six-week tolerability of Simvastatin 80 and 160 mg/day
    Davidson, MH
    Stein, EA
    Dujovne, CA
    Hunninghake, DB
    Weiss, SR
    Knopp, RH
    Illingworth, DR
    Mitchel, YB
    Melino, MR
    Zupkis, RV
    Dobrinska, MR
    Amin, RD
    Tobert, JA
    [J]. AMERICAN JOURNAL OF CARDIOLOGY, 1997, 79 (01) : 38 - 42
  • [7] Farnier M, 1997, ATHEROSCLEROSIS, V134, P123
  • [8] FARNIER M, 1997, ATHEROSCLEROSIS, P134
  • [9] INSULL W, 1997, J AM COLL CA SA 0229, pA46
  • [10] ISAACSOHN J, 1998, 13 INT S DRUGS AFF L, P62